- Home
- VNRX vs TPST Comparison
VNRX vs TPST Comparison
Compare VNRX & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNRX | TPST |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 30.9M |
| IPO Year | 2012 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VNRX | TPST |
|---|---|---|
| Price | $0.20 | $1.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 12.0M | 59.5K |
| Earning Date | 03-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | 21.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,233,511.00 | $295,000.00 |
| Revenue This Year | $68.22 | N/A |
| Revenue Next Year | $382.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.10 | N/A |
| 52 Week Low | $0.17 | $0.60 |
| 52 Week High | $0.94 | $12.22 |
Technical Indicators
Market Signals| Indicator | VNRX | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 26.62 |
| Support Level | $0.17 | N/A |
| Resistance Level | $0.27 | $2.49 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 21.99 | 11.39 |
Price Performance
Historical ComparisonAbout VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.